Gritstone/GRTS

$0.77

3.94%
-
1D1W1MYTD1YMAX

About Gritstone

Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.

Ticker

GRTS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Andrew Allen

Employees

231

Headquarters

Emeryville, United States

Gritstone Metrics

BasicAdvanced
$78.93M
Market cap
-
P/E ratio
-$1.55
EPS
0.66
Beta
-
Dividend rate
$78.93M
0.66459
$3.33
$0.67
2.9M
3.198
77.423
77.423
-66.18%
-124.41%
-77.72%
4.829
1.403
1.522
-18.04%
-11.81%
59.38%

What the Analysts think about Gritstone

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
571.43% upside
High $10.00
Low $3.00
$0.77
Current price
$5.17
Average price target

Gritstone Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-299.02% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$10.3M
586.67%
Net income
$-30.8M
-19.79%
Profit margin
-299.02%
-88.32%

Gritstone Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 20.7%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.30
-$0.31
-$0.33
-$0.26
-
Expected
-$0.33
-$0.35
-$0.33
-$0.33
-$0.32
Surprise
-10.31%
-10.53%
-0.86%
-20.7%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Gritstone stock?

Gritstone (GRTS) has a market cap of $78.77M as of April 21, 2024.

What is the P/E ratio for Gritstone stock?

The price to earnings (P/E) ratio for Gritstone (GRTS) stock is 0 as of April 21, 2024.

Does Gritstone stock pay dividends?

No, Gritstone (GRTS) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Gritstone dividend payment date?

Gritstone (GRTS) stock does not pay dividends to its shareholders.

What is the beta indicator for Gritstone?

Gritstone (GRTS) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Gritstone stock price target?

The target price for Gritstone (GRTS) stock is $5.17, which is 598.65% above the current price of $0.74. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Gritstone stock

Buy or sell Gritstone stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing